-
Mashup Score: 18The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype - 1 day(s) ago
At a recent Oncologic Drugs Advisory Committee (ODAC) Meeting, the U.S. Food and Drug Administration (FDA) laid out its rationale for rejecting the supplem
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Is Your Cancer Test Accurate? The FDA Wants to Make Sure - 2 day(s) ago
A new rule details how the agency will oversee the $10 billion industry for medical tests conducted by single laboratories.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Are we all one overhead bin battle away from an in-flight meltdown? - The Boston Globe - 9 day(s) ago
Maybe we should accept reality — this is who we are — and play to our strengths.
Source: www.bostonglobe.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Is That A.I. Mammogram Worth the Cost? (Gift Article) - 23 day(s) ago
The new add-on service for breast exams can cost between $40 and $100. We asked experts to separate the sales pitch from the science.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Compensation for senior bosses at firms from Tesla to T-Mobile US worth more than those companies’ net tax payments, study finds
Source: www.theguardian.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Compensation for senior bosses at firms from Tesla to T-Mobile US worth more than those companies’ net tax payments, study finds
Source: www.theguardian.comCategories: General Medicine News, Hem/OncsTweet
Important editorial on how investigator exuberance for new drugs may diminish the validity of clinical trials results, and how FDA and pharma should think about that. Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype https://t.co/mAAoZwwHhH